Becton Dickinson and Company (BDX)vsLeMaitre Vascular Inc (LMAT)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
LMAT
LeMaitre Vascular Inc
$111.08
+0.99%
HEALTHCARE · Cap: $2.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 8684% more annual revenue ($21.92B vs $249.60M). LMAT leads profitability with a 23.1% profit margin vs 8.0%. BDX appears more attractively valued with a PEG of 1.16. LMAT earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
LMAT
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Margin of Safety
+26.1%
Fair Value
$118.87
Current Price
$111.08
$7.79 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Keeps 23 of every $100 in revenue as profit
Strong operational efficiency at 21.8%
15.7% revenue growth
Earnings expanding 41.4% YoY
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : LMAT
The strongest argument for LMAT centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 21.8%. Revenue growth of 15.7% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : LMAT
The primary concerns for LMAT are PEG Ratio, P/E Ratio. A P/E of 43.7x leaves little room for execution misses.
Key Dynamics to Monitor
BDX profiles as a value stock while LMAT is a growth play — different risk/reward profiles.
LMAT carries more volatility with a beta of 0.68 — expect wider price swings.
LMAT is growing revenue faster at 15.7% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 61/100). LMAT offers better value entry with a 26.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →LeMaitre Vascular Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?